{"prompt": "['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', '(28). Given the wide overlap of clinical, immunological and histological features of PPP and', 'plaque-type psoriasis in conjunction with the observation that apremilast also effectively', 'targets the innate immune system (e.g. neutrophils) it may be speculated that apremilast can', 'successfully be used in the treatment of PPP.', 'The planned study is a multicenter, open label, single-arm pilot study intended to gain', 'information on safety, clinical efficacy and the mechanistical effects of apremilast on PPP.', '6.2', 'Potential Risks and Benefits', 'According to the \"summary of the risk management plan (RMP) for Otezla\u00ae (apremilast)\\' (29),', 'by blocking the action of PDE4, apremilast reduces the symptoms of psoriasis and psoriasis', 'arthritis. Because of exclusion of patients with moderate / severe kidney disorders, liver', 'disorders, children and pregnant or breastfeeding patients from clinical trials, there is no', 'information on safety or effectiveness of Otezla\u00ae for these patients. However, these patient', 'groups will also be excluded for the clinical study presented here.', 'Important identified risks include:', 'weight decrease in patients with Body Mass Index (BMI) <20 kg/m\u00b2', 'depression', 'Important potential risks include:', 'inflammation of blood vessels (vasculitis)', 'risk of triggering suicide (suicidal thoughts)', 'tumors (malignancies)', 'nervousness and anxiety', 'serious infections', 'major heart problems (major adverse cardiac events [MACE] and tachyarrhythmia)', 'effects on the developing child if used during pregnancy', 'For more detailed information on these identified and potential risks please refer to the', '\"summary of the risk management plan (RMP) for Otezla\u00ae (apremilast)\\' (29) and the \\'Rote', \"Hand Brief' (30).\", 'Otezla\u00ae has been approved for the treatment of patients with moderate to severe plaque', 'psoriasis and for the treatment of patients with active psoriatic arthritis. Overall, no serious', 'safety issues are associated with Otezla\u00ae and the benefit-risk profile for Otezla\u00ae is acceptable', 'and the risks can be mitigated though professional labeling.', 'Page 23 of 75']['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', '7', 'Study Objectives and Purpose', '7.1', 'Primary Objective', 'The primary objective of this study is:', 'To demonstrate a significant improvement of PPPASI at week 20 compared with', 'baseline in moderate to severe chronic palmoplantar pustulosis under apremilast', 'therapy.', '7.2', 'Secondary Objective(s)', 'The secondary objectives of the study are:', 'To evaluate an improvement of PPPASI at all assessment times compared with', 'baseline in moderate to severe chronic palmoplantar pustulosis under apremilast', 'therapy.', 'To evaluate differences during the treatment with apremilast in life quality assessment', 'measures: Dermatology Life Quality Index (DLQI) at all assessment times compared', 'with baseline', 'To evaluate safety of apremilast in patients with moderate to severe palmoplantar', 'pustulosis', 'Exploratory objectives are:', 'Time course of Hand and Feet Physician Global Assessment (H&F PGA) at all', 'assessment times.', 'Pustules count 50 response and Pustules count 75 response, defined as a 50% and', '75% decrease in Pustules count from baseline, during the 20 weeks treatment period', 'To evaluate differences in the mean change from baseline at all assessment times of', 'VAS pruritus / itch, VAS discomfort / pain at all assessment times relatively to day 0', '(baseline)', 'To evaluate changes in Psoriasis Area Severity Index (PASI), Physician Global', 'Assessment (PGA) and dynamic H&F PGA if plaque psoriasis is present between', 'baseline and all assessment times', 'To explore the effect of apremilast on immunological markers in serum / plasma', 'To explore the effect of apremilast on immunological markers in skin biopsies (sub-', 'study, see Section 12.1.10.2)', 'Page 24 of 75']\n\n###\n\n", "completion": "END"}